Hygiene & infection prevention network

Research insights from ICPIC 2021

October 06, 2021 Dr. Marco Bo Hansen Season 2 Episode 15
Hygiene & infection prevention network
Research insights from ICPIC 2021
Show Notes Transcript

On this podcast, we are pleased to share a collection of short conversations with the researchers from the International Conference on Prevention & Infection Control (ICPIC) in Geneva, Switzerland, between 14 – 17th September.

ICPIC offers a unique platform for researchers and experts worldwide to share their knowledge and practices concerning the prevention of healthcare-associated infections and control of antimicrobial resistance. 

In this podcast, you will hear conversations about interesting topics with:

  • Matuesz Gajda who is doing his Ph.D. in Microbiology at Jagiellonian University in Kraków.
  • Adriënne van der Schoor, PhD student currently working at Erasmus Medical Centre in Rotterdam. 
  • Delphine Berthod and Christelle Perdrieu, both working at Swissnoso in the surgical site infection surveillance.
  • Dr. Prabin Shrestha, a representative of the Young Professional Development Society in Nepal.
  • Dr. Taru Singh, working as a scientist in a Counsel of Medical Research in New Delhi, India.



Wed, 10/6 1:02 PM • 16:44


patients, poster, infection, Nepal, hand hygiene, hospital, sharing, important, attend, infection prevention, conference, India, antimicrobial resistance, problem, surgical site infections, insights, antimicrobial stewardship, work, medical doctors, hospitals


Dr. Marco Bo Hansen, Adriënne van der Schoor, Matuesz Gajda, Delphine Berthod and Chriselle Perdrieu, Dr. Prabin Shrestha, Dr. Taru Singh


Dr. Marco Bo Hansen  00:02

Hi, I'm Marco, and thanks for listening in. I'm a medical doctor and researcher. My mission is to empower healthcare workers to prevent infectious diseases. Each episode is a short conversation with experts sharing their insights with us. Hi, and welcome to the hygiene and infection prevention network. We are recording here from the epic conference in Geneva, Switzerland. And we are very curious to hear what people have learned and what they have seen from interesting studies and presentations. And here with me, I have Matthew. So we'll come back to you. Hi, Mateusz, can you tell us a bit about yourself, where you're from and what you're doing?


Mateusz Gajda  00:45

Yes, my name is Matuesz Gajda. I'm from Poland University Hospital in Cracow. I'm doing my Ph.D. at the microbiology department at Jagiellonian. University in Cracow, also. And I'm here with four posters. So Wow. Many of those.


Dr. Marco Bo Hansen  01:05

Okay, so you are very skilled in research. Can you tell us about one of your posters and the results?



Yeah, I think the most important is about pneumonia, after hip and knee arthroplasty. We work on a huge national database from National Health found in Poland. And this is so important because we noticed that patients are not too well prepared for those surgeries. Now. Yeah, there are almost 80,000 patients during the year. We have data from 2017. But we notice that prayer or post-hospital rehabilitation reduces the risk of pneumonia, but those patients don't have this revelation. So this is I think, the most important also, the second conclusion is that the patients discharged with antibiotics also have a higher risk of infection like pneumonia, or urinary tract infection.


Dr. Marco Bo Hansen  02:03

Okay. Thank you for sharing that. Have you also attended some of the presentations?



Yeah, of course, I think I attended mostly about the Clostridium difficile lab because I had one poster also on this topic. Okay. Yeah. But it's interesting learning. This post, I think, is still a,significant problem. In Poland, we have a lot of cluster Gae. There Are infections, despite antibiotics in patients, which are longer in hospital, but we observe it without any, I think, any factor that could increase the risk, but they are also plus three years. So it's curious why that's happened. Maybe those are some factors, which we don't know for now. So yeah, I attend mostly such conferences, but I think it's epic. Also, we noticed that this colonisation of some pets, also dogs, I think cats with cluster Veritas which we don't think about everyday. That might be our future, we'll have this.


Dr. Marco Bo Hansen  03:06

Yes. Important learnings. You mentioned that you are currently a PhD, system researcher at koco. University Hospital. How is it there with hospital acquired infections? Do you know the numbers or I think



Nowadays in time of COVID is hard to say anything else about COVID but I think this post is still a significant problem. In my department. I work in oncology. So vascular medicine, I think we don't have any week without any hospital-acquired infection, mostly cluster datasets. I said, Yeah. But yeah, I think this poses a significant problem. I think we still need to do something with these five hygiene moments of our hands. Yeah, there's still a lot to do. Yes,


Dr. Marco Bo Hansen  03:53

exactly. So much more room for improvement. Yeah,



yeah, of course. So those conferences, I think, are very important and needed. And there's maybe only a few medical doctors attending and they're taking some microbiology departments and sad, but it will change.


Dr. Marco Bo Hansen  04:14

Yeah, I agree. More physicians, more medical doctors, media, also to focus on this very important topic.



Yeah. Also that the surgical site infections are also a huge problem. I will do it for further research. database, which we had, but yeah, we show that almost 30% of infections in this database, which we get are also surgical site infections. So it is a huge problem.


Dr. Marco Bo Hansen  04:38

I think the new numbers from Denmark, estimates that the surgical site infections cost society around 1 billion Danish krone so that would be a huge number 1.5 Actually, I don't know how much that would be in



the currency. Yeah, I think that's huge, bro. Because we don't think about these prolonged complications that there's another cost after this infection after, we don't have the screening of patients after discharge, except as cute problems. Well, thank


Dr. Marco Bo Hansen  05:14

you so much for taking your time. Thank you and have a nice conference.



Thank you.


Dr. Marco Bo Hansen  05:20

Hi, and welcome to the podcast again. Together with me, I have Adrian, welcome. Thank you. Thank you very much. Adrian, can you tell us a bit about yourself and why you're here?


Adriënne van der Schoor  05:30

Yes, of course. My name is Adriënne van der Schoor, I work at the Erasmus Medical Centre in Rotterdam in the Netherlands. And I'm a final year PhD student. And this was my first life foreign conference I was able to attend. So I'm very happy to


Dr. Marco Bo Hansen  05:44

be here. Yeah. And how is it to get out and meet people? Again?



It's a bit surreal, but pretty nice. Pretty nice. Yeah.


Dr. Marco Bo Hansen  05:53

And what is your research about?



Well, in 2018, the house was empty, relocated to a new hospital building. And now we have only single patient rooms with private bathrooms. And well, the old building had multiple occupancy rooms. So I'm looking at if that relocation kind of affected the acquisition of resistant microorganisms, and if the environment is cleaner, and there's also some microbiome analysis. Yeah,


Dr. Marco Bo Hansen  06:19

We see similar trends. I'm from Denmark, and the hospitals are centralising going from also multiple bedrooms to single bedrooms. So I'm curious to hear Do you have any results that you can share yet,



It's still very preliminary, but I presented some results in magnets last year to digital one. And I can share that kind of data. So power with a very low prevalence of HR mode and endurance. So we were unable to see any differences for MSA or fury or those gains. But we did look at esbl producing and so went back to Dallas. Yeah. Which we didn't really see an effect for, we did see that patients were less transferred in the new hospital building. And we find a positive correlation between the transfers and acquisitions of esbl. Ease. So there's an indirect effect.


Dr. Marco Bo Hansen  07:06

Okay, that's very interesting. Yeah.



So as well, based on


Dr. Marco Bo Hansen  07:11

the data so far, do you think it's a good idea to have single patient bedrooms?



I think so. I think so. There's also a lot of other sides. And we're also in a consortium that looks at multiple things. There's also the isolation of the patients who work for the healthcare workers. But solely based on infection prevention, I think it's very useful, especially to bathrooms, private bathrooms for everyone. That's a really good idea. Yeah. And we also see that the environment is a bit cleaner. Yeah. We found a loveless HMO in the environment.


Dr. Marco Bo Hansen  07:41

Yeah, that sounds promising. That sounds promising.



Yeah. But we should look at if there's also effective COVID because there's obviously a lot more disinfection. Yeah. So maybe that still kind of shifts the results of it. looks very promising.


Dr. Marco Bo Hansen  07:56

Sounds very interesting. I'm looking. Thank you so much for taking your time. I'm looking forward to it. Hopefully I can hear more about your results next week. Thank you very much. Thank you. Can you please introduce yourself?


Delphine Berthod and Chriselle Perdrieu  08:10

My name is Delphine working with Swiss Nosal deflecto. In the SSI surgical site infection surveillance, we both work there in the team. But I also work as an infectious disease petitioner and epidemiologists in my hospital in Valley, so where I have a lot to do with COVID those days,


Dr. Marco Bo Hansen  08:28

so you have been very busy lately. Very, very busy. Very



busy. Yeah. And I'm Chriselle. So I started working for Swiss nozzle three months ago. You were very new, and I'm a project manager, leading the project for the surveillance of subjective states and fiction in Switzerland. That's perfect.


Dr. Marco Bo Hansen  08:46

And if you should highlight something, what did you particularly like from the conference?



I liked it a lot to further tweak it. We'll come together here. It's great for us to come together, learning together and sharing our experiences and you know, watching together a topic and being able to share about it. And of course, the fact that we meet again, people, it's so nice to see people again. But of course we miss a lot because I remember two years ago, there were so many people from abroad, and it was great to share with them. So we miss them a lot, because there are a lot of them who could not travel. So


Dr. Marco Bo Hansen  09:23

Yeah, we are missing them. Hopefully they will be able to join the next conference.



They will for sure. Yeah, well, exactly the same. And I'm even more happy to be here because as I said, I'm very new in this field. So for me, it's just learning a lot from all the presentations, all the discussions.


Dr. Marco Bo Hansen  09:42

Perfect. Thank you so much for sharing your insights. Thank you. And we live here from geek pick and welcome to you. Can you please introduce yourself?


Dr. Prabin Shrestha  09:52

Yes, thank you very much. I am Dr. Prabin Shrestha, and I'm from Nepal. So I am involved with an organisation called Young Professional Development Society, Nepal. So we basically work in the field of health. Yes,


Dr. Marco Bo Hansen  10:02

That's great. And I know that you have a postdoc here at epic. Can you tell us about what we actually have to remember ? Yes. Okay, let me hear.



Okay. So regarding the posters, I had two posters, poster presentations in this epic. The first poster was regarding the status of drug resistant tuberculosis infection control in the context of Nepal, another one poster was littered with the burden of drug resistant tuberculosis in Nepal. So, out of the two posters, I will be explaining something about the burden of drug resistant TB in Nepal, I will talk about this poster. So regarding the burden of drug resistant tuberculosis in Nepal, what we found out is that there is a huge gap between the notified sorry, between the estimated and notified cases, actually. So, I think there is a gap of around 60% of cases that are actually missing. There is a huge gap between those estimated and the notified cases. And another thing is that, regarding the treatment enrollment of the notified cases, we are identifying less cases. And among them also, we are enrolling less patients into treatment, actually. So there is a huge gap between the notified and the treatment cases also. So what we conclude is that in the context of Nepal, we still need to work more in the field of drug resistant tuberculosis control, so that there are last cases actually, because those cases are actually spreading the disease to the other people. So it's time that we need to identify them, we need to identify those notified cases. So if we are able to bring those cases into treatment, then we are able to control the spread of drtv infection. Yes.


Dr. Marco Bo Hansen  11:34

And thank you for these important insights. Any presentations you're looking forward to?



Yes, I think there is a session this afternoon about hand hygiene. So I'm particularly interested and looking forward to that session, actually. So because hand hygiene is one of the greatest tools, let's say, for infection control. And in the context of COVID-19. At this moment, hand hygiene is definitely the best tool for prevention and control of infection. So I'm looking forward to that. And maybe there are some new insights into our new evidence regarding hand hygiene. So I'm looking forward to those sessions.


Dr. Marco Bo Hansen  12:09

I'm sure there is . Thank you for sharing your insights.



Thank you very much.


Dr. Marco Bo Hansen  12:14

With me now, I would like to welcome Taru,



Thank you so much. It's my great pleasure to be with you.


Dr. Marco Bo Hansen  12:21

Can you please share with us where you're from, where you're working, what you're working with?


Dr. Taru Singh  12:24

Sure. I'm Dr. Singh. I'm basically from New Delhi, India. I'm working as a scientist at Indian Council of medical research, a major government body. And we provide support to the major hospitals in India. We have networks all over India. And we are like a hierarchy. We are giving training to the bigger hospitals in turn, they are giving training to their smaller hospitals, nursing homes, and our project is on antimicrobial resistance. Basically, we are working on the antimicrobial stewardship programme and infection prevention and control. I'm myself very new to this field. I have just joined six months back. So it's a great exposure for me to attend this conference at a very early stage of my career.


Dr. Marco Bo Hansen  13:15

Yeah, conferences idea right to attend any of you attended any interesting presentations that you want to highlight,



Yes, I have attended multiple presentations basically on COVID. Because being from the developing countries, we are facing so many problems regarding COVID, addressing surveillance and vaccination basically. And apart from that, I have found that whole genome sequencing very interesting. I attended it yesterday. And it was very nice, we got to know what should be done. We have very specific and particular labs in India, which are working on sequencing so that we can correlate the samples of the patients from different areas from North India to South India, east to west, and the whole genome sequencing is the best platform to build a database and give a better result and so that we can analyse the results at a later stage. So I learned so many things from here. And apart from that, I also had a poster yesterday for that I got a travel grant as well.


Dr. Marco Bo Hansen  14:19

Oh, congratulations. Thank you so much. Please tell us about your poster. What's it about?



It's about antimicrobial resistance in the paediatric population up to five years of age because my focus on a lot of pathogens was equalised. It's basically diarrheagenic, since in India the mortality due to damage earnings equalise too high and I thought that's part of my PhD work as well. So I thought of extending this to my scientific area. So it was basically focused on the paediatric population. And in that I looked into the various beta lactamase genes. focused on what is the area and how it transmits from population to population, from community to patients. So I looked and found that there is a promoter sequence and beta lactamase that is basically important for the transmission of this resistance from the community, and from the patient to the community, and then back to the patients. So it's like a cycle, which always occurs in a population, I guess,


Dr. Marco Bo Hansen  15:30

How do we break that cycle? What do you think?



I think we need to focus on the antimicrobial stewardship, because we are using antimicrobials just like that, without any stop on that without any recommendations by the doctor or the physicians. Everybody's taking their own antimicrobials. They're searching on Google and just talking by themselves without any particular timeline or guidelines. So we need to break that. That's why our project in which I'm currently working, it's totally focused on this. It's basically introductory, that platform to sensitise. The smaller hospitals because they're unaware of that hand hygiene, and basic things regarding entry microbiologists and how it spreads and how it contributes to the antimicrobial resistance in paediatric population. Also,


Dr. Marco Bo Hansen  16:23

Tara, thank you so much for sharing your insights. Let's catch up. I'm looking forward to hearing more about your research. Thank you.



Thank you so much.